Rita Santacroce

Dr. Rita Santacroce

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Giovanni MartinottiGiovanni Martinotti
Giovanni Martinotti
RSRita Santacroce
Rita Santacroce
Mauro PettorrusoMauro Pettorruso
Mauro Pettorruso
CMChiara Montemitro
Chiara Montemitro
MSMaria Chiara Spano
Maria Chiara Spano
ALArturo G. Lerner
Arturo G. Lerner
Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs. The aims of the present study are to review all the original studies about HPPD in order to evaluate the following: (1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD induction; (3) the clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities; and (5) the available and potential therapeutic strategies. We searched PubMed to identify original studies about psychedelics and Hallucinogen Persisting Perception Disorder (HPPD). Our research yielded a total of 45 papers, which have been analyzed and tabled to provide readers with the most updated and comprehensive literature review about the clinical features and treatment options for HPPD.

28 July 2015 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
GMGiovanni Martinotti
Giovanni Martinotti
MLMatteo Lupi
Matteo Lupi
LCLeonardo Carlucci
Leonardo Carlucci
ECEduardo Cinosi
Eduardo Cinosi
RSRita Santacroce
Rita Santacroce
MGMassimo Di Giannantonio
Massimo Di Giannantonio

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
FBFrancesco Saverio Bersani
Francesco Saverio Bersani
OCOrnella Corazza
Ornella Corazza
GAGabriella Albano
Gabriella Albano
Giuseppe ValerianiGiuseppe Valeriani
Giuseppe Valeriani
RSRita Santacroce
Rita Santacroce
FSFabrizio Schifano
Fabrizio Schifano
Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim of this paper is to provide a comprehensive review of the nature and the risks associated with 25C-NBOMe, which has recently appeared in the drug market.Methods. A systematic analysis of the scientific literature and a qualitative assessment of online and media resources (e.g., e-newsgroups, chat-rooms, and e-newsletters) in 10 languages were carried out.Results. 25C-NBOMe is sold online as legal LSD or as research chemical with different designations such as “Boom,” “Pandora,” “Holland film,” or “N-bomb.” It is a partial agonist of 5-HT2A receptors. It is usually ingested orally/sublingually and, less commonly, nasally, through injection, vaginally, rectally, and smoked. Its effects include sublingual numbing, stimulation, “body high,” hallucinations, dissociation, and anxiety. 25C-NBOMe presents high risk of overdoses; acute toxicity and fatalities have been reported.Conclusions. 25C-NBOMe consumption represents an emerging phenomenon with potential harmful effects. Its use is increased by its online availability at low costs. Health and other professionals should be informed about this new trend of substance use.

15 July 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
GMGiovanni Martinotti
Giovanni Martinotti
MLMatteo Lupi
Matteo Lupi
TATiziano Acciavatti
Tiziano Acciavatti
ECEduardo Cinosi
Eduardo Cinosi
RSRita Santacroce
Rita Santacroce
MGMassimo di Giannantonio
Massimo di Giannantonio
Objective. Comorbidities between psychiatric diseases and consumption of traditional substances of abuse (alcohol, cannabis, opioids, and cocaine) are common. Nevertheless, there is no data regarding the use of novel psychoactive substances (NPS) in the psychiatric population. The purpose of this multicentre survey is to investigate the consumption of a wide variety of psychoactive substances in a young psychiatric sample and in a paired sample of healthy subjects.Methods. A questionnaire has been administered, in different Italian cities, to 206 psychiatric patients aged 18 to 26 years and to a sample of 2615 healthy subjects matched for sex, gender, and living status.Results. Alcohol consumption was more frequent in the healthy young population compared to age-matched subjects suffering from mental illness (79.5% versus 70.7%;P<0.003). Conversely, cocaine and NPS use was significantly more common in the psychiatric population (cocaine 8.7% versus 4.6%;P=0.002) (NPS 9.8% versus 3%;P<0.001).Conclusions. The use of novel psychoactive substances in a young psychiatric population appears to be a frequent phenomenon, probably still underestimated. Therefore, careful and constant monitoring and accurate evaluations of possible clinical effects related to their use are necessary.

1 September 2013 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
GMGiovanni Martinotti
Giovanni Martinotti
MLMatteo Lupi
Matteo Lupi
FSFabiola Sarchione
Fabiola Sarchione
RSRita Santacroce
Rita Santacroce
ASAnatolia Salone
Anatolia Salone
MGMassimo Giannantonio
Massimo Giannantonio
Pregabalin is an anticonvulsant drug that binds to the α2δ (alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.

15 June 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
OCOrnella Corazza
Ornella Corazza
GMGiovanni Martinotti
Giovanni Martinotti
RSRita Santacroce
Rita Santacroce
ECEleonora Chillemi
Eleonora Chillemi
MGMassimo Di Giannantonio
Massimo Di Giannantonio
SCSelim Cellek
Selim Cellek
Introduction. The use of unlicensed food and herbal supplements to enhance sexual functions is drastically increasing. This phenomenon, combined with the availability of these products over the Internet, represents a challenge from a clinical and a public health perspective.Methods. A comprehensive multilingual assessment of websites, drug fora, and other online resources was carried out between February and July 2013 with exploratory qualitative searches including 203 websites. Additional searches were conducted using the Global Public Health Intelligence Network (GPHIN). Once the active constitutes of the products were identified, a comprehensive literature search was carried out using PsycInfo and PubMed.Results. The most common sexual enhancement products available on the Internet were identified. Their active ingredients included yohimbine, maca, horny goat weed andGinkgo biloba.These four substances were reported with the occurrence of adverse events and the induction of psychological symptoms, such as mood changes, anxiety, and hallucinations as well as addictive behaviours.Conclusions. Uncontrolled availability of sexual enhancement products that contain potentially harmful substances is a major public health concern. The possible impact on population health, particularly among subjects with psychiatric disorders, usually at risk for sexual dysfunction, may be significant. This new trend needs to be extensively studied and monitored.